BioLineRx sells APHEXDA royalty rights to Soleus Capital for $5.6 million
BLRX•
BLRX•BioLineRx agreed to sell its 14.4% APHEXDA royalty interest to Soleus Capital for a one-time $5.6 million payment. The proceeds will support GLIX1 development and other corporate purposes, including partial repayment of a BlackRock loan that will eliminate a $4 million minimum cash balance requirement.
BioLineRx agreed to sell its 14.4% APHEXDA royalty interest to Soleus Capital for a one-time payment of $5.6 million. BioLineRx will retain potential commercial milestone payments under its Ayrmid license agreement and royalties attributable to periods before closing.
The company plans to use the proceeds for GLIX1 clinical development, working capital and general corporate purposes, including partial repayment of a BlackRock loan. That repayment will eliminate the existing $4 million minimum cash balance requirement. Closing is expected on or about November 30, 2026.